Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter.
Oramed Pharmaceuticals Trading Down 0.5 %
NASDAQ ORMP opened at $2.15 on Wednesday. The firm has a market cap of $86.67 million, a PE ratio of 19.55 and a beta of 1.66. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67. The stock has a 50-day moving average of $2.33 and a 200-day moving average of $2.36.
Analyst Upgrades and Downgrades
Separately, StockNews.com cut shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
- Five stocks we like better than Oramed Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What is the Nikkei 225 index?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Trading Halts Explained
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
